J Korean Ophthalmol Soc > Volume 55(3); 2014 > Article
Journal of the Korean Ophthalmological Society 2014;55(3):391-395.
DOI: https://doi.org/10.3341/jkos.2014.55.3.391    Published online March 15, 2014.
Factors Influencing the Effect of the Intravitreal Bevacizumab Injection in Patients with Central Serous Chorioretinopathy.
Eui Yong Kweon
Department of Ophthalmology, Chonbuk National University Medical School, Jeonju, Korea. key@jbnu.ac.kr
중심장액맥락망막병증 환자에서 유리체강내 베바시주맙 주입술의 치료 효과에 영향을 주는 요인
권 의 용
Department of Ophthalmology, Chonbuk National University Medical School, Jeonju, Korea
Abstract
PURPOSE
To evaluate the factors influencing the effect of the intravitreal bevacizumab injection in patients with central serous chorioretinopathy. METHODS: We performed a retrospective review of the medical records of 54 patients (56 eyes) who had been symptomatic for more than 3 months with central serous chorioretinopathy (CSC), who had undergone intravitreal bevacizumab injection and been on regular follow-up for at least 6 months. RESULTS: Responders were 34 eyes (60.7%) and non-responders were 22 eyes (39.3%). The leaking points of the non-responder group were multiple and located more centrally than that of the responder group on fluorescein angiography (FA) (p = 0.01, p = 0.044). In addition, non-responder group showed cystoid macular edema on optical coherence tomography (OCT) as compared with responder group (p = 0.042). CONCLUSIONS: CSC with multiple, centrally located leaks on FA or cystoid macular edema on OCT was ineffective or recurrent with intravitreal bevacizumab injection.
Key Words: Bevacizumab;Central serous chorioretinopathy


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next